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1. Introduction
  Mortality and morbidity due to malaria is still substantial 
in many tropical countries. In 2006, 247 million cases of 
malaria were estimated, resulting in 881 000 deaths[1]. Of 
the 109 endemic countries, 30 countries in sub-Saharan 
Africa and five in Asia account for 98% of malaria deaths 
globally[2].  Yet, the actual burden of disease in these areas 
is not known due to under-reporting. It is estimated that 
the total incidence of malaria is decreasing in Bhutan, Sri 
Lanka, Thailand and North Korea, while the number of 
Plasmodium falciparum (P. falciparum) infections has risen 
in Bangladesh, India, Myanmar and Timor Leste[1]. Large-
scale preventive campaigns, focusing on vector control, 
chemotherapy, and education have been used in the battle 
against this protozoan parasite which, with its innate 
complexities, continuously challenges human populations.
  This paper concentrates on chemoprophylaxis and its 
consequences on the disease burden of malaria. In an ideal 
situation, such chemoprophylaxis should prevent all cases 
of malaria, be well tolerated and cost effective. If properly 
administered, it should prevent mortality and morbidity 
from malaria. However, such a perfect chemoprophylactic 
agent does not exist. This fact is made evident by the 
widely varied chemoprophylactic regimens recommended 
for different parts of the world. Different genetic mutations, 
and the selection pressure for these mutations, have 
rendered several drugs and drug combinations useless 
in some settings. As for side effects and toxicity, many 
drugs used in prophylaxis have disturbing side effects, 
including gastrointestinal, neurological and haematological 
disturbances[3]. These factors make it difficult to 
recommend a universally acceptable prophylactic regimen 
against malaria. Specific drugs or drug combinations for 
malaria prophylaxis have to be defined for each region, 
taking into consideration locally prevalent parasite 
mutants, cost effectiveness and public acceptance; this is a 
continuous challenge.
2. Methods
  A  MEDLINE search was performed for all articles with the 
key word ‘Malaria’ in the title field and ‘Prophylaxis’ in 
any field. The search was restricted to articles published 
in English within the last decade (1999-2009). There 
were 2 621 abstracts in the original search with these 
restrictions. The software Endnote X2 was used to filter 
articles. Bibliographies of cited literature were also 
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searched. All abstracts were read independently by the 
three authors, and key articles were identified based on a 
consensus among all authors. Related or cited papers were 
also included. Sources were screened for relevance to the 
topic (articles based on chemoprophylaxis with reference 
to individual drugs or combinations, their use in pregnancy 
and evidence on cost effectiveness). Data sources included 
review articles published in core clinical journals, cohort 
studies, interventional studies, case control studies and 
cross sectional analyses. The epidemiological data were 
downloaded from the websites of international agencies, 
such as the World Health Organization (WHO).  
3. Protection against clinical malaria
  Various drugs and their combinations have been assessed 
in the prevention of clinical malaria. Currently, chloroquine, 
proguanil, mefloquine and doxycycline are all used for 
standard prophylaxis[4]. However, the success of these 
regimens depends on the drug-sensitivity patterns of local 
strains of Plasmodium. The following subsections discuss 
the specific issues related to each drug or combination used 
in the prophylaxis of malaria. 
4. Chloroquine
  Chloroquine has been used since the 1940s in the treatment 
and prophylaxis of malaria. This drug is concentrated 
within the food vacuole of the parasite (where haemoglobin 
is degraded) and inhibits the polymerization of toxic heme 
to hemazoin[5]. Chloroquine is indicated for treatment and 
prevention of all types of malaria where sensitivity persists [6].
Unfortunately, resistance to chloroquine is widespread, 
particularly for falciparum malaria. Resistance is mainly 
determined by the selection of a mutant form of the P. 
falciparum chloroquine resistance transporter gene (pfcrt) 
which effects chloroquine transport across the digestive 
vacuole of the parasite[7].  In many sub-Saharan countries, 
chloroquine is virtually ineffective as a prophylactic agent. 
A few countries in Central America and Central Asia still 
maintain complete sensitivity to chloroquine[6]. 
  Chloroquine resistant vivax malaria is another problem. It 
was first reported from Papua New Guinea in 1989[8]. Since 
then cases have been reported from a vast geographical 
area spanning the continents of Asia (Indonesia, Myanmar, 
India and Turkey), Africa (Ethiopia) and South America 
(Brazil, Peru, Colombia). In all these areas, chloroquine 
resistant falciparum malaria is also reported and therefore 
chloroquine is not recommended  for prophylaxis[6].
  The side effect profile of chloroquine is well established 
and common problems include gastrointestinal disturbances 
and blurred vision. Though less common, other adverse 
effects include chloroquine-induced retinopathy, pruritus 
and mood changes[3].
  Given the extent of resistance, despite being a safe and 
cheap choice, chloroquine alone cannot be recommended 
for prophylaxis in many endemic malaria regions today. 
5. Mefloquine
  Mefloquine was introduced in the 1970s as a synthetic 
analogue of quinine. Its exact mechanism of action is 
unclear. However, it is thought to form toxic complexes 
with heme, which damage the membranes of the parasitic 
organelles[9]. Mefloquine is used mainly in the treatment 
and prophylaxis of chloroquine resistant malaria, and 
trials have shown it to have good efficacy in this regard[10]. 
However, P. falciparum resistance to mefloquine has also 
been reported (though not widespread), making it less useful 
as a prophylactic agent in some areas of South East Asia [11]. 
Again, the exact mechanism of resistance is unclear, but 
mutations in the P. falciparum multiple drug resistance gene 
(pfmdr1) are implicated[12-16].
  Another deterrent to its use are its side effects, in particular 
neuropsychiatric effects.  It is known to cause severe 
depression, anxiety, insomnia, nightmares, seizures and 
neuropathy. However, several studies comparing the side 
effect profile of mefloquine with other standard regimens 
have concluded that, in doses used for prophylaxis, it is no 
more toxic than other therapies[17]. Indeed, it was found to 
be more tolerable than doxycycline when considering both 
neuropsychiatric and gastrointestinal side effects[18]. 
  Mefloquine can be recommended for prophylaxis in many 
malaria areas of the world. Despite some disturbing side 
effects, the risk-benefit assessment supports its use in 
malaria prevention. 
6. Sulfadoxine-pyrimethamine (SP)
  The combination of sulfadoxine and pyrimethamine has 
been used in the treatment and prevention of malaria since 
the 1970’s. These antifolate drugs have a long half-life and 
their presumed mechanism of action involves interfering 
with folate metabolism of the parasite by inhibiting the 
dihydrofolate reductase (DHFR) and dihydropteroate 
synthatase enzymes[19]. Its indications include prophylaxis 
and treatment of drug-resistant chloroquine malaria. 
However, SP is a failed drug for prophylaxis in many sub 
Saharan regions[20,21]. The mechanism of resistance is 
attributed to mutations in the parasite genes encoding the 
enzymes of folate metabolism. Nonetheless, SP has a special 
indication in prophylaxis. In areas with stable P. falciparum 
malaria in Africa, WHO recommends a regimen known as 
intermittent preventive therapy (IPT) for pregnant women, 
infants and children (see subsection on pregnancy). SP is the 
only recommended drug for such therapy in Africa based 
on trial evidence[19,22]. The exact mechanism of action of SP 
in IPT is unclear, but is thought to be related to its ability 
to clear the parasite and suppress asymptomatic infections. 
The longer half life due to slow clearance enables it to 
maintain an efficacious plasma concentration over a longer 
period of time compared with other drugs/combinations. 
This may prevent the occurrence of new infections in the 
weeks following its administration. 
  However, the emerging patterns of resistance and the 
side effect profile have caused concern with regards to the 
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continued use of SP. The potentially serious side effects of 
SP include haematological problems, such as megaloblastic 
anaemia, thrombocytopaenia and leucopaenia, pulmonary 
infiltrates with eosinophilia, peripheral neuropathy, and 
cutaneous manifestations, such as Stevens-Johnson 
syndrome[3]. 
  Current opinion on the use of SP in prophylaxis is that it 
should be restricted to the special indication of IPT. It is not 
recommended for travelers to endemic areas[3, 6].
7. Proguanil and its combinations
  Proguanil was developed in the late 1940s and its 
mechanism of action involves inhibiting the dihydrofolate 
reductase enzyme of the parasite and blocking DNA 
synthesis. However, when given alone, resistance can 
develop rapidly against it[4]. Therefore, it is used in 
combination with either chloroquine or atovaquone (which 
has a different mechanism of action against the parasite) to 
treat and prevent chloroquine resistant malaria.   
  In combination with chloroquine, proguanil has been 
shown to reduce the clinical burden of malaria significantly 
compared to a placebo[23], but has also been shown to be 
less efficient than mefloquine or atovaquone-proguanil 
combination[10]. Resistance to this combination has been a 
problem due to the pfcrt mutation affecting the chloroquine 
component, and, hence, currently, it is not the preferred 
choice of prophylaxis in sub Saharan Africa[6]. The main 
side effects include gastrointestinal disturbances (including 
nausea, diarrhoea and stomatitis) and rarely cholestasis. 
  On the contrary, the combination of atovaquone-proguanil 
(malarone) was shown to have excellent efficacy in 
prophylaxis, particularly against falciparum malaria, with 
a good safety profile in several trials[24, 25]. Nonetheless, 
evidence for prophylactic failure with malarone emerged 
in the 2001-2005 period. Though this observation is not 
evidence of widespread resistance to malarone, it can be 
a potential problem in the future as there could be many 
locals infected with these resistant strains. It has been 
demonstrated that mutations in the cytochrome b gene 
(which codes for the mitochondrial enzyme involved in 
cellular respiration and is critical for survival) is associated 
with delayed recrudescence of the parasite with malarone [26].
  The main side effects of malarone include gastrointestinal 
disturbances, insomnia, dizziness and headache. Overbosch 
et al[27], in a large-scale, randomized clinical trial, have 
shown that the protective efficacy of this combination was 
as good as that of mefloquine, with comparatively less 
side effects, in particular with regard to gastrointestinal 
disturbances and stomatitis. Riemsdijk et al[28] have also 
shown that a mefloquine treated group had higher scores 
of depression, anxiety and anger compared with those on 
malarone treatment. 
8. Primaquine
  Primaquine has a somewhat different role in the 
chemoprophylaxis of malaria. The drug has been used since 
the 1950s, although its mechanism of action is not yet fully 
understood. Theoretically, the indications for primaquine, as 
supported by trial evidence, are three-fold. It can be used 
as a primary prophylactic agent, as a terminal prophylactic 
agent and in radical cure regimens for ovale and vivax 
malaria . Resistance to primaquine is rarely reported[29].  
  However, there are two factors limiting its use as a primary 
prophylactic agent; side effects and cost. The major side 
effect of primaquine is its ability to precipitate glucose 6 
-phosphate dehydrogenase (G6PD) deficiency. It is not cost 
effective for prophylaxis when costs of testing for G6PD 
status of recipients are considered[30]. Furthermore, its use 
in pregnancy is contraindicated as the G6PD status of the 
foetus cannot be routinely assessed[31]. Thus, primaquine 
is currently not recommended by the WHO for primary 
prophylaxis[6].
  Nonetheless, primaquine has a place in chemoprophylaxis 
in several special situations. Firstly, in patients with 
Plasmodium vivax (P. vivax) or Plasmodium ovale (P. ovale) 
infection treated with anti-malarials, despite the clearance 
of blood parasites,  relapses could occur due to the 
reactivation of hypnozoites in the liver (P. falciparum does 
not have hypnozoites in its life cycle).  Primaquine is used to 
eliminate the hypnozoites of P. vivax and P. ovale species, 
thus preventing clinical relapses. Since vivax malaria 
is the more prevalent form of malaria outside of Africa, 
particularly in Asia, primaquine plays a role in preventing 
clinical disease in such areas. 
  Secondly, primaquine has been suggested to have a role 
in terminal prophylaxis (medication taken towards the end 
of the exposure period).  Chloroquine and primaquine are 
usually used in combination for this purpose on the premise 
that chloroquine enhances the hypnozoite clearance effect of 
primaquine. However, Soto et al(1999). have demonstrated 
that the combination of primaquine and chloroquine did not 
add to the protective efficacy against falciparum malaria, 
or, more surprisingly, against vivax malaria (as P. vivax was 
sensitive to chloroquine in this locality) when compared 
with primaquine alone. Though the trial was carried out in a 
limited number of individuals (<200), this interesting aspect 
has not been examined in detail by anyone else[32,33]. In our 
opinion, the role of primaquine in terminal prophylaxis (in 
adult, non-immune, non-pregnant travelers) needs to be 
re-assessed with regard to cost and benefit. Even if the costs 
of testing for G6PD status are considered, it might prove 
beneficial as local outbreaks from relapses in non-immune 
communities (after travelers return home) can be avoided.
  Finally, primaquine can be used to prevent the 
transmission of falciparum malaria. In patients treated 
with chloroquine or artesunate, primaquine is effective in 
eradicating circulating gametocytes, which are infective to 
the vector/s.  Thus, it acts as a chemoprophylactic agent 
at a community level by interrupting the transmission of 
falciparum malaria. 
9. Antibiotics
  Doxycycline is a semisynthetic tetracycline used in malaria 
prophylaxis. Its antibacterial action involves inhibition 
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of protein synthesis, and the same mechanism may kill 
plasmodia.  Doxycycline is shown to have good efficacy in 
areas of chloroquine resistant malaria[34]. However, data on 
resistance patterns have not been reported. 
  There is concern about its side effects limiting compliance. 
The commonly reported side effects include gastrointestinal 
disturbances, flushing and tinnitus. It cannot be used in 
pregnant women, and its use in children is not advised 
due to dental staining. The preparation of doxycycline will 
also determine the severity of side effects. For example, 
doxycycline monohydrate caused less gastrointestinal 
disturbances than doxycycline hyclate and also had a better 
side effect profile than chloroquine- proguanil[34]. However, 
another trial by Sonmez et al has shown doxycycline to 
cause more side effects than mefloquine; the preparation of 
doxycycline was not mentioned in this paper[18]. 
  Azithromycin is a macrolide antibiotic with limited 
evidence in malarial prophylaxis in comparison with 
doxycycline. It also acts by interfering with protein 
synthesis. Daily administration of azithromycin as a 
prophylactic regimen was shown to be effective against 
vivax malaria[35,36]. However, the evidence for protection 
against falciparum malaria is less convincing, as one trial 
had too few falciparum infections (four in azithromycin 
group and five in control group) to permit a valid statistical 
analysis[35]. Another trial showed a protective efficacy of only 
71.6% against falciparum malaria (as opposed to a protective 
efficacy of 98.9% against P. vivax)[37]. Data on resistance 
patterns for azithromycin is not available. Its main side 
effects are gastrointestinal disturbances.
  In summary, none of these drugs offer complete 
protection against malaria (depending on the geographical 
area). Chloroquine and SP resistance is widespread in 
many malarial areas. The combination of proguanil and 
chloroquine is recommended for some of these areas, but 
resistance is developing rapidly[6]. On the other hand, 
doxycycline, atovaquone-proguanil (malarone) and 
mefloquine are effective in many areas of multidrug resistant 
malaria. Compliance is another issue that has a direct 
impact on efficacy of various regimes. A less disturbing side 
effect profile, shorter duration of prescription and lesser 
frequency of therapy (daily vs weekly administration) would 
improve compliance. 
10. Prophylaxis and pregnancy
  It is estimated that 50 million women become pregnant 
annually in areas endemic for malaria, and 50% of them 
are in sub Saharan Africa[19]. Malaria in pregnancy carries 
many risks for the mother as well as for the baby, and such 
risks are greater in the first and second pregnancies[38]. 
Not only are these women vulnerable to severe malaria 
infection, but, once infected, the disease is more likely to 
progress to complications, including cerebral malaria and 
pulmonary oedema. Infection during pregnancy causes high 
parasitaemia, a greater degree of anaemia and a higher risk 
of stillbirth due to parasitic sequestration in the placenta. 
Therefore, the prevention of malaria during pregnancy, 
particularly in primigravidae, should be a priority in high 
prevalence regions. In general, travel to endemic regions 
is discouraged during pregnancy. However, in unavoidable 
circumstances, the benefits of prophylaxis have to be 
balanced against the risks of infection and the side effects of 
drugs. 
  Apart from tetracycline and related drugs, other drugs used 
in prophylaxis have not caused significant teratogenicity, 
and some authors consider them safe for use during 
pregnancy[31]. However, the wider consensus is that, where 
firm evidence for safety is lacking, especially for mefloquine 
and malarone, it is prudent to use an alternative  unless the 
resistance patterns deems their use as essential[3, 6]. 
The possible combinations that may be used in pregnancy 
include chloroquine alone, chloroquine-proguanil, 
mefloquine, atovaquone-proguanil and SP[31]. However, 
in our opinion, data are still lacking to recommend 
atovaquone-proguanil (to be avoided unless essential) and 
mefloquine for widespread use in pregnancy. Primaquine is 
not considered safe for reasons mentioned previously.  
  The most efficacious combination of drugs depends on 
the locally prevalent Plasmodium species and resistance 
patterns and therefore varies between regions[39]. 
Chloroquine has been used over many years for prophylaxis 
against both P. vivax and P. falciparum infections during 
pregnancy with a well established safety profile. Despite 
widespread resistance, its use still has a positive impact 
on pregnancy outcomes (reduction in low birth weight, 
less maternal anaemia, reduced maternal parasitaemia) 
compared with no prophylaxis, presumably in people 
infected with sensitive strains[40,41]. A randomized placebo 
controlled trial for primigravid mothers in Uganda showed 
that weekly prophylaxis with chloroquine results in 
better outcome than passive case management in terms of 
improved maternal haemoglobin levels and improved birth 
weights of babies[42]. Salihu et al[40]. reported similar findings 
for chloroquine prophylaxis from a study in Cameroon. In 
this group, maternal parasitaemia declined significantly 
(26.3% vs. 44.9%) in the treatment group, and the low 
birth rates also declined, though not significantly (P=0.16). 
Studies of the use of chloroquine during pregnancy in Asia 
are few. Villegas et al conducted a double blind randomized 
trial (n=1 000) of weekly prophylaxis with chloroquine (300 
mg base) vs. placebo for pregnant women (primigravid or 
multigravid) In Thailand[43]. The results have demonstrated 
that prophylaxis with chloroquine offers protection against 
vivax malaria. However, no significant difference was 
observed with relation to the occurrence of falciparum 
malaria compared with a placebo.  
  The combination of chloroquine with proguanil has been 
assessed in areas with chloroquine resistance, with good 
results. The disadvantage is that the chloroquine-proguanil 
combination needs to be administered over many weeks to 
maintain the protective effect, which could lead to resistance 
due to over-exposure. The evidence on safety of the 
atovaquone-proguanil combination is not well established to 
recommend its use during pregnancy.  
  Mefloquine has a teratogenic effect at high doses in 
animals. However, two studies in humans have not 
demonstrated any adverse effects. One trial in Thailand 
(trimester not specified) showed that the mefloquine group 
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was no different from a quinine-treated group in terms of 
adverse pregnancy events (eg preterm labour and foetal 
distress), and another small study on 20 women exposed to 
mefloquine in pregnancy in the third trimester showed no 
adverse outcome for infants after a follow up of 2 years[44, 45]. 
Both studies demonstrated no teratogenicity. However, the 
lack of exposure data in the first trimester calls for caution 
in its use[6]. 
  As early as in 1994, it was shown that SP (Sulfadoxine 
500mg and pyrimethamine 25 mg) administered in two 
intermittent doses during the second trimester and at the 
beginning of the third trimester was more effective in 
reducing peripheral and placental parasitaemia than the 
traditional long term prophylactic regimen of chloroquine[46]. 
The prolonged effect of the combination was partly attributed 
to the long half-lives of both components of the drug, though 
its exact mechanism of protection is not fully understood. 
Since the mid 1990s, this combination was adopted as 
the main mode of prophylaxis during pregnancy in many 
endemic areas of Africa and became known as intermittent 
preventive therapy (IPT). Though it has had a positive impact 
on preventing malaria to date, reports of emerging resistance 
have cast doubt on its future role in prophylaxis[47]. Another 
potentially unexplored, yet theoretically important issue, 
is the widespread use of cotrimoxazole in the treatment 
of HIV, which is shown to induce cross-resistance 
between sulfadoxine and sulfamethoxazole moieties and 
pyrimethamine and trimethoprim moieties[48]. The effects 
of the loss of efficacy of SP, which is the only recommended 
combination for IPT, would be considerable; a search for a 
replacement combination is urgently needed. 
  One alternative is the combination of chloroquine with 
azithromycin which has been shown to have synergistic 
activity (in vivo) against P. falciparum in trials in Africa 
and India (azithromycin 1 000 mg and chloroquine 600 mg 
daily for 3 days) when used in non pregnant adults[49, 50]. 
If used in IPT, both drugs are safe to be administered at 
any time during pregnancy with the additional benefits 
of preventing/treating sexually transmitted infections 
(STIs) and pneumococcal infections during pregnancy. 
There are two limiting factors in using this regimen for 
prophylaxis; the high cost of azithromycin and the risk of 
wide spread resistance to azithromycin with large scale 
population exposure. Also for parasitological clearance, 
the combination has to be taken over three days (unlike 
the single dose of SP) and ensuring compliance with direct 
observation may be problematic[51]. Clinical trials are yet to 
assess the practicality and efficacy of using this combination 
for IPT.
  In summary, chloroquine and chloroquine-proguanil 
combination have been evaluated in numerous clinical 
trials and found to be efficacious in improving maternal 
and neonatal outcome and exhibiting a good safety profile. 
Sulfadoxine-pyrimethamine is used in intermittent 
prophylactic therapy in areas of stable P. falciparum 
transmission with efficacy, but resistance is becoming 
a significant problem. Currently, there is inadequate 
evidence of the safety and efficacy of mefloquine or 
proguanil-atovaquone for use during pregnancy. The use 
of either tetracycline group of antibiotics or primaquine is 
contraindicated during pregnancy.
11. The cost factor
  The costs involved in malaria prophylaxis are not restricted 
to the monetary value (direct cost) of the drugs used. It also 
involves indirect costs such as laboratory tests (eg testing for 
G6PD deficiency before primaquine administration), costs 
of treatment in failure of prophylaxis, and costs of treatment 
of side effects. Our calculations for direct costs of short 
term prophylaxis of people traveling into endemic areas 
have shown that, without any terminal prophylaxis with 
primaquine, doxycycline is the cheapest regimen of those 
considered by the British Medical Association for travelers 
to endemic areas[3]. Chloroquine alone is very cheap but 
ineffective in many endemic areas. Mefloquine was twice 
more expensive than chloroquine-proguanil for a one week 
stay. Atovaquone-proguanil was the most expensive of all.  
  Queries have been raised about the cost effectiveness of 
non-selective prescription of prophylaxis to travelers going 
in to areas of low incidence (eg Sri Lanka). A survey in 
eight European countries has shown that the total number 
of infections imported from the Indian subcontinent 
(including India, Bangladesh, Pakistan and Sri Lanka) is 
less than 5% of the total number of malaria cases reported, 
and is on the decline[52]. Given the low risk, some authors 
argue that stopping non-selective prescription for travelers 
in to the subcontinent is more cost effective[52]. Though 
it can be argued that the low rate of infection is due to 
effective prophylaxis, another survey in departure lounges 
at European airports has shown that only 22% of travelers 
comply with prescribed/recommended prophylaxis regimens [53]. 
  The situation is different for people living in areas endemic 
for malaria. While the choice of drugs is determined by 
the local resistance patterns, the duration of prophylaxis 
has to be long term and possibly annually with each 
transmission season. Benefits such as improvement of 
working capacity, reduction of low birth weight deliveries, 
cognitive development of younger generations and overall 
improvement of well-being become the major advantages in 
this setting. Some of these benefits are difficult to quantify 
in terms of money but nevertheless important. At the same 
time, considering the risks of long term prophylaxis is also 
pertinent. Retinopathy (with macular and perimacular 
degeneration) is known to occur with the long-term use of 
chloroquine, and prophylactic regimens have precipitated 
such morbidity. Polyneuropathy is another complication of 
long-term chloroquine use. Any serious side effect, even if 
not associated with long-term use, may cause concerns if a 
drug is to be recommended for widespread use (chloroquine: 
haematological abnormalities, dyskinesias, seizures, and 
hypotension; SP: Steven Johnson syndrome and blood 
dyscrasias). These complications make it difficult to analyze 
and formulate a cost-effective regimen applicable to a vast 
geographical area of high endemicity. 
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12. Conclusions
  Mortality and morbidity from malaria show a significant 
shift from the situation three decades ago. The malaria 
burden in some regions, such as South Asia, has declined 
significantly while it is still a major cause of mortality and 
financial distress in sub Saharan Africa. Prophylaxis has 
implications in both these settings, to break the cycle of 
infection and move towards elimination in South Asia, 
and to reduce the disease burden in sub Saharan Africa. 
Unfortunately, resistant forms of the parasite have emerged 
against all regimens of prophylaxis used to date, and the 
problem is significantly greater in the most affected regions 
of Africa. The development of resistance against cheaper 
drugs of prophylaxis, such as chloroquine and SP, is 
widespread in several malaria hotspots. 
  Malaria prophylaxis has shown clear benefits in 
reducing maternal anaemia and the incidence of low birth 
weight in endemic countries. The cost effectiveness of 
universal prophylaxis for travelers into the subcontinent 
is controversial, given the low risk of infection; more 
selective prescription of prophylaxis will be useful. The 
cost effectiveness of prophylactic regimens for people living 
in endemic areas is difficult to estimate, because of the 
complex hidden costs and benefits involved. The importance 
of having a centralized government-controlled anti-malaria 
programme to limit the exposure of the human population 
to different drug regimens is demonstrated in two ways; 
to save money and to delay the emergence of resistance 
which ultimately results in a successful phase out towards 
elimination. 
  Two reliable sources for detailed information on malaria 
prophylaxis for travelers are the ‘International Travel and 
Health Report, 2009’ and the  ‘Travelers Health – Yellow 
book’ which are published by the WHO and the Center for 
Disease Control (CDC) respectively[6, 54]. 
  Areas needing further research are; assessing the efficacy 
and safety of prophylactic regimens in the elderly and the 
immunocompromised, quantification of the prevalence of 
resistance to individual regimens in endemic areas and 
options for replacing SP in intermittent preventive therapy. 
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